Maiwei Biotech announced that the company's new antibody-conjugated drug 9mW2821 targeting nectin-4 will report its phase I/II clinical research data and latest developments for various advanced solid tumors in the form of an oral report at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. 9MW2821 is the first domestic company to conduct clinical trials among same-target drugs. It is also the first same-target drug in the world to disclose clinical efficacy data for cervical cancer, esophageal cancer, and breast cancer indications. Current clinical research results have shown outstanding efficacy and safety of treatment.
迈威生物：9MW2821在多种晚期实体瘤的I/II期临床研究中显示突出的治疗有效性与安全性
Maiwei Biotech: 9MW2821 showed outstanding therapeutic efficacy and safety in phase I/II clinical studies of various advanced solid tumors
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.